How lenalidomide is changing the treatment of patients with multiple myeloma.
about
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in KoreaImmunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.No clinically significant drug interactions between lenalidomide and P‑glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers.Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients.Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myelomaTherapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents
P2860
Q26992002-BEDC2E12-FCFA-4EB7-818D-35F6FBE56010Q35801267-649E79C6-7F9E-43DA-A8CD-7DAB9BC4293FQ37724506-4B6EF721-5A5D-41B3-8996-308913B9FC25Q38530066-7DB2E642-8004-4584-BEFF-35B1E231258AQ38749573-39246320-B6A0-4B1B-9C2D-E3505D73DFBCQ49048515-CCECBE74-B206-4FBD-9D19-7CA78EE394D8Q57904195-863CC7FE-60EE-46BE-AFE2-8014751C8CB4Q57904303-40DBACAC-7924-462F-A846-012615B7B7D7
P2860
How lenalidomide is changing the treatment of patients with multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
type
label
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
prefLabel
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
P1476
How lenalidomide is changing the treatment of patients with multiple myeloma.
@en
P2093
Evangelos Terpos
P304
P356
10.1016/J.CRITREVONC.2013.05.013
P478
88 Suppl 1
P577
2013-06-28T00:00:00Z